Online inquiry

IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12328MR)

This product GTTS-WQ12328MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets TIGIT gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_173799.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 201633
UniProt ID Q495A1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12328MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ14126MR IVTScrip™ mRNA-Anti-PCSK9, aPCSK927(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aPCSK927
GTTS-WQ11881MR IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLN-0264
GTTS-WQ13196MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-04950615
GTTS-WQ10604MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY3300054
GTTS-WQ7231MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-G4h-28-F9Z-TpERt CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-G4h-28-F9Z-TpERt CAR
GTTS-WQ9584MR IVTScrip™ mRNA-Anti-EGFR&MET, JNJ-61186372(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-61186372
GTTS-WQ6937MR IVTScrip™ mRNA-Anti-TNF, ENIA11(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ENIA11
GTTS-WQ13696MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RC48
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW